- Congresos
- IMCAS Americas - abril 2025
- IMCAS Asia - junio 2025
- IMCAS China - julio 2025
- IMCAS World Congress - enero 2026
- Masterclases
- IMCAS India - noviembre 2025
- Congresos
- IMCAS Americas - abril 2025
- IMCAS Asia - junio 2025
- IMCAS China - julio 2025
- IMCAS World Congress - enero 2026
- Masterclases
- IMCAS India - noviembre 2025

IMCAS Academy

Presentación
Inscribirse
Programa
Oradores
Gala
Planifique su viaje
Enviar un resumen
Listado de sponsors
Acreditación
Prensa

VOLVER

IMCAS Asia 2025
Programa

Contributed Talks - Clinical dermatology

Sala: Room 2 - Level 2
Fecha: domingo 8 junio 2025 de 16:00 a 17:00
Formato: CONTRIBUTIVA > presentaciones que fueron cuidadosamente revisadass y seleccionadas por el Consejo Científico. basadas en presentaciones y/o resúmenes recibidos

Las presentaciones

Horas	Oradores	Título de la presentación	Resumen	Número
16:00	Dr Anood AL ISSA	From scar to solution: dupilumab's emerging promise in treating keloids' cosmetic and functional challenges	Ver	147168
16:10	Dr Lixia LI	Efficacy of the combination therapy of intense pulsed light and microneedling with a postbiotic formulation for melasma	Ver	147169
16:20	Dr Rajkiran TAKHARYA	Efficacy of topical timolol drops in the management of pyogenic granuloma of lip	Ver	147170
16:30	Dr Victoria G BELO	Innovative approach to facial pigmentary disorders: a pilot study on combined pulsed dye laser, RF microneedling, and rose stem cell-derived exosomes	Ver	147171
16:40	Dr Gisela TRAJANO SARMIENTO	Scars imprint: its many battles and diverse management	Ver	147172
16:50		Q&A		147173

Ver sesiones anteriores

Ver la sala siguiente (Room 3 - Level 2)

Sesiones recomendadas

Cicatrices

Tratamientos combinados

Dispositivos de energía (EBD)

Láseres

Pigmentación

Dr Anood AL ISSA

Dermatólogo

Jordania

Otro(s) autor(es) :

From scar to solution: dupilumab's emerging promise in treating keloids' cosmetic and functional challenges

Objectives: - Investigate dupilumab's role in keloid treatment.
- Examine its modulation of IL-4 and IL-13 pathways.
- Assess the efficacy and safety of dupilumab through case reviews.
- Analyze varying treatment outcomes.
- Enhance decision-making in keloid management based on patient-specific factors.
- Understand the complex nature of keloid pathophysiology.

Introduction: Keloid scars, characterized by excessive collagen deposition from abnormal wound healing, present significant cosmetic and functional challenges. Traditional treatments, such as intralesional steroids and surgical excision, often yield limited results. Dupilumab, a cutting-edge IL-4 and IL-13 pathway inhibitor, has emerged as a novel therapeutic option. Initial case studies reveal promising outcomes, though variability in results highlights the need for further research to fully determine its effectiveness and refine its role in keloid management.

Materials / method: This review investigates the potential of dupilumab in treating keloid scarring through an extensive literature search. We explored PubMed, MEDLINE, and Embase using targeted Medical Subject Headings and keywords related to dupilumab and keloids. The search focused on recent, peer-reviewed articles, clinical trials, and reviews. We meticulously selected studies based on relevance, and rigorously extracted and synthesized data to evaluate dupilumab’s efficacy and safety in addressing keloid scarring.

Results: Keloids, characterized by excessive scarring from abnormal healing, remain challenging to treat due to their high recurrence rates. While traditional methods like steroids and surgical excision often fall short, dupilumab, targeting IL-4 and IL-13, has shown promise in reducing keloid size and symptoms, particularly in patients with coexisting atopic dermatitis. However, responses varied, with some patients improving significantly while others saw minimal or no benefit. These results highlight the importance of further exploration to optimize therapeutic approaches and enhance outcomes.

Conclusion: Dupilumab, targeting IL-4 and IL-13 signaling, emerges as a promising adjunct in managing keloid scarring, especially for cases resistant to traditional therapies. While some patients have shown notable improvements in keloid size and symptoms, variability in outcomes and limited long-term data necessitate cautious optimism. Personalized treatment plans and ongoing research are crucial to optimize dupilumab's role in keloid therapy, address potential biases, and establish its efficacy and safety profile comprehensively.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Dr Lixia LI

Dermatólogo

China

Otro(s) autor(es) : Zhanhong Li, Qiong Meng.

Efficacy of the combination therapy of intense pulsed light and microneedling with a postbiotic formulation for melasma

Objectives: To assess the clinical effectiveness of the combination therapy of intense pulsed light (IPL) and microneedling with a postbiotic lotion containing Lactobacillus fermentation lysate in facial melasma, with the objective of developing a comprehensive and effective treatment strategy for melasma.

Introduction: Intense pulsed light (IPL) alleviates skin pigmentation by the principle of selective photothermolysis. Lactobacillus fermentation lysate has the potential to repair the skin barrier and inhibit melanin production. Microneedling not only accelerates melanin metabolism and promotes skin self-repair but also enhances the transdermal absorption of therapeutic agents. However, the effectiveness and safety of the combination application of all three for melasma management remains to be fully elucidated.

Materials / method: Thirty participants were randomly divided into two groups. The IPL therapy group received IPL treatment (wavelength: 590-640 nm, pulse width: 3.0-4.0 ms, pulse delay: 40-50 ms, energy density: 14-18 J/cm2) at four-week intervals over a consecutive period of twelve weeks. The combination therapy group participated in a regime where IPL therapy and microneedling (needle length: 0.5 mm) were alternately carried out every two weeks throughout the 12-week treatment duration. The postbiotic lotion was applied immediately after the microneedling procedure.

Results: Compared to the baseline, both the IPL therapy group and the combination therapy group exhibited a significant reduction in the mMASI score, and the combination therapy group was more effective. The evidence of clinical photographic and VISIA-derived statistical data indicated that patients receiving the combined therapy experienced a decrease in facial speckle, a reduction in inflammation, and an improvement in hyperpigmentation, with over 73% of participants expressing very satisfied or satisfied. No significant adverse reactions were reported.

Conclusion: Our study demonstrated that combination therapy yielded significantly greater efficacy than IPL monotherapy. This combined treatment exhibited multiple synergistic benefits, including inflammation reduction, accelerated melanin metabolism, the restoration of skin microecological equilibrium and skin barrier enhancement. These advancements promoted postoperative skin recovery and reduced the incidence of adverse effects, presenting a promising therapeutic approach for individuals diagnosed with melasma.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo es presentado gracias al apoyo de: Guangzhou LTHINK Biotechnology Co. Ltd. (Guangdong, China); Guangzhou MLT Medical Cosmetic Clinic, Guangzhou, China.

Dr Rajkiran TAKHARYA

Dermatólogo

India

Otro(s) autor(es) :

Efficacy of topical timolol drops in the management of pyogenic granuloma of lip

Objectives: efficacy of Topical Timolol Drops in the Management of Pyogenic Granuloma of
Lip

Introduction: Pyogenic granuloma, also referred to as granuloma pyogenicum, is a prevalent, non-cancerous vascular tumor that develops in various tissues, including the skin and mucous membranes. The medically precise term for this condition is lobular capillary hemangioma. Treatment options include cauterization (either chemical or thermal), laser therapy, surgical excision, curettage, sclerotherapy, and cryotherapy. Additionally, topical timolol is gaining recognition as a non-invasive treatment option for pyogenic granulomas.

Materials / method: Individuals of both genders were enrolled in the study if they had pyogenic granuloma lesions that had been present for less than six weeks. A topical application of 0.5% timolol was administered thrice daily over a period of eight weeks. Evaluations were made regarding alterations in color, size, propensity to bleed, and any side effects experienced.

Results: All 10 patients demonstrated a full response within 8 weeks, and there was no recurrence observed during the 1-month follow-up. Additionally, none of the patients reported any local or systemic side effects.

Conclusion: Topical timolol administered as drops may be an effective, safe, and cost-efficient treatment for mucosal pyogenic granulomas. While topical timolol could be considered for early-stage pyogenic granulomas, further studies with extended durations are necessary to evaluate the rates of resolution and recurrence.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Dr Victoria G BELO

Dermatólogo

Filipinas

Otro(s) autor(es) : Jacqueline M. Luna, MD, John Paul Jalandoni, MD

Innovative approach to facial pigmentary disorders: a pilot study on combined pulsed dye laser, RF microneedling, and rose stem cell-derived exosomes

Objectives: This case series aims to evaluate the combined effect of Pulsed Dye Laser (PDL), Radiofrequency Microneedling (RFM), and Rose Stem Cell-Derived Exosomes on various forms of facial pigmentation and assess the safety and tolerability of the combined treatment.

Introduction: Facial pigmentation disorders, including melasma, solar lentigines, acne scars, and post-inflammatory hyperpigmentation, can be challenging to treat especially in patients with darker skin types. Previous studies have demonstrated the efficacy of individual treatments such as pulsed dye laser (PDL), radiofrequency (RF) microneedling, and topical exosomes.

Materials / method: The study included 11 female patients aged 36 to 48 years, the majority of whom have Fitzpatrick skin type IV (73%), while the remainder are skin type III (27%). Patients underwent various combinations of PDL, RFM, and topical exosomes, with sessions ranging from (2) to (10) for PDL, (2) to (8) for RFM, and (2) to (8) for exosomes. Photographs and Visia skin analysis were used for monitoring results.

Results: Results showed that patients who received more sessions of the combined treatments generally experienced better improvement in facial pigmentation. Notable improvements were observed in conditions such as melasma, solar lentigines, and post-inflammatory hyperpigmentation. Visia skin analysis showed an average reduction of spots and brown spots by 31%. All patients tolerated the combination treatment well, and no severe adverse events were reported, indicating a favorable safety profile. This multimodal approach shows synergistic benefits with combined PDL, RFM, and topical exosomes.

Conclusion: There is benefit to combination therapy with PDL, RFM, and exosomes treatment; however, variability in treatment response suggests that individual factors such as skin type and the number of sessions may influence outcomes. The study’s small sample size and lack of a control group limit the generalizability of the findings, and the absence of long-term follow-up precludes conclusions about the durability of treatment effects. Future research should include larger, controlled studies to validate these findings and assess the long-term efficacy and safety of this combination therapy.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Dr Gisela TRAJANO SARMIENTO

Dermatólogo

Filipinas

Otro(s) autor(es) :

Scars imprint: its many battles and diverse management

Objectives: To Explore and integrate new and emerging technologies in scar management, such as stem cell therapy, PRP (Platelet-Rich Plasma), Chromatherapy, and innovative laser therapies and many more, to improve healing outcomes.

Introduction: Scars of whatever nature is aesthetically unsightly. It often presents a decrease of self-esteem to a person. Unfortunately, it is prevalent all over the globe. The Philippines is one of many countries with a scar-stricken population.

Nowadays, many options are available for the treatment of scarring, including chemical peeling, dermabrasion, laser treatment, punch techniques, fat transplantation, other tissue augmenting agents, needling, subcision, and many combined therapies. Various modalities have been used to treat scars, but limited efficacy and problematic side effects have restri

Materials / method: Power point presentation

Results: This lecture will tackle various types of scars from which it may be useful for selecting the best therapeutic strategy, whether it be single or combined therapy while reducing or avoiding the side effects and complications.

Delegates will learn innovative treatments in scar management

Conclusion: Ultimately, scar management is an ongoing process that requires a tailored, patient-centered approach. As new technologies and treatment options continue to emerge, there is immense potential to improve outcomes and offer hope for individuals seeking to minimize the impact of scars on their lives. Through comprehensive care, it is possible to achieve not only improved scar appearance but also enhanced quality of life for those affected.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Q&A

CONGRESO en

0 3 7

DíAS EN BANGKOK

¿Tiene una pregunta?

Encuentre las respuestas rápidamente en nuestra sección de FAQ.

Congresos

IMCAS Americas
IMCAS Asia
IMCAS China
IMCAS World Congress

Acerca de

Empresa
Política de Confidencialidad
Mención legal

Academy

Inicio
Cursos
Webinars
Explorar
Blog

Subvenciones

Subvención educativa

Ponerse en contacto

Contáctenos

Nombre de usuario/Email

Contraseña

Mantenerme conectado

Iniciar sesión

Olvidé mi contraseña ? Todavía no tiene una cuenta? Inscríbase ahora

Mantenerme conectado

academy.Do_not_have_an_account_yet Inscríbase ahora

IMCAS Asia 2025 Programa

Contributed Talks - Clinical dermatology

Las presentaciones

Sesiones recomendadas

IMCAS Asia 2025
Programa